KOD News and Press, Kodiak Sciences Inc From 05/15/23

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and com...

2023-05-01 17:27:57 ET Gainers: Woodward ( WWD ) +19% . SI-BONE ( SIBN ) +7% . Sprouts Farmers Market ( SFM ) +6% . Kodiak Sciences ( KOD ) +5% . Neuronetics ( STIM ) +5% . Losers: Travere Therapeutics ( TVTX ) -25%...

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting PR Newswire PALO ALTO, Calif. , April 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researchi...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

(NewsDirect) Kodal Minerals PLC (AIM:KOD) chief executive Bernard Aylward speaks to Proactive about some recent drilling at the company's Bougouni lithium project in Mali, before going on to provide an update on the latest news about the financing of the development. Hainan Mining Co ...

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases PR Newswire PALO ALTO, Calif. , April 3, 2023 /PRNewswire/ -- Kodia...

2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...

2023-03-28 16:50:52 ET Kodiak Sciences press release ( NASDAQ: KOD ): Q4 GAAP EPS of -$1.35 beats by $0.19 . Kodiak ended the fourth quarter of 2022 with $478.9 million of cash, cash equivalents and marketable securities. For further details see: Kodiak Scien...

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , March 28, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, d...

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting PR Newswire PALO ALTO, Calif. , Feb. 9, 2023 ...